MA28515B1 - Inhibiteurs de gsk-3 - Google Patents

Inhibiteurs de gsk-3

Info

Publication number
MA28515B1
MA28515B1 MA29364A MA29364A MA28515B1 MA 28515 B1 MA28515 B1 MA 28515B1 MA 29364 A MA29364 A MA 29364A MA 29364 A MA29364 A MA 29364A MA 28515 B1 MA28515 B1 MA 28515B1
Authority
MA
Morocco
Prior art keywords
gsk
inhibitors
compounds
thiadiazolidinc
alzheimer
Prior art date
Application number
MA29364A
Other languages
English (en)
Inventor
Gil Martinez
Diaz Isabel Dorronsoro
Cascon Mercedes Alonso
Pliego Gema Panizodel
Huerta Ana Fuertes
Puerto Maria Jose Perez
Padilla Miguel Medina
Original Assignee
Noscira Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28515(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noscira Sa filed Critical Noscira Sa
Publication of MA28515B1 publication Critical patent/MA28515B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
MA29364A 2004-04-05 2006-10-02 Inhibiteurs de gsk-3 MA28515B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04075997A EP1586318A1 (fr) 2004-04-05 2004-04-05 Thiazolidinones comme inhibiteurs de GSK-3

Publications (1)

Publication Number Publication Date
MA28515B1 true MA28515B1 (fr) 2007-04-03

Family

ID=34928129

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29364A MA28515B1 (fr) 2004-04-05 2006-10-02 Inhibiteurs de gsk-3

Country Status (30)

Country Link
US (2) US7531561B2 (fr)
EP (2) EP1586318A1 (fr)
JP (1) JP4995076B2 (fr)
KR (1) KR101151647B1 (fr)
CN (1) CN1946398B (fr)
AR (2) AR048820A1 (fr)
AT (1) ATE446090T1 (fr)
AU (1) AU2005230392B2 (fr)
BR (1) BRPI0508788A (fr)
CA (1) CA2559740C (fr)
CY (1) CY1109724T1 (fr)
DE (1) DE602005017215D1 (fr)
DK (1) DK1586319T3 (fr)
EC (1) ECSP066858A (fr)
ES (1) ES2335505T3 (fr)
HK (1) HK1100426A1 (fr)
HR (1) HRP20100032T1 (fr)
IL (1) IL178125A (fr)
MA (1) MA28515B1 (fr)
MX (1) MXPA06011194A (fr)
NO (1) NO332751B1 (fr)
NZ (1) NZ549904A (fr)
PL (1) PL1586319T3 (fr)
PT (1) PT1586319E (fr)
RS (1) RS51340B (fr)
RU (1) RU2379300C2 (fr)
SI (1) SI1586319T1 (fr)
TW (1) TWI352084B (fr)
WO (1) WO2005097117A1 (fr)
ZA (1) ZA200608221B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1286964B1 (fr) 2000-05-11 2007-07-04 Consejo Superior de Investigaciones Cientificas Inhibiteurs heterocycliques de la glycogene synthase kinase gsk-3
EP1586318A1 (fr) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiazolidinones comme inhibiteurs de GSK-3
WO2006045581A1 (fr) * 2004-10-21 2006-05-04 Neuropharma, S.A. Utilisation de 1, 2, 4-thiadiazolidine-3, 5-diones en tant qu'activateurs de ppar
ES2258406B1 (es) * 2005-02-10 2007-12-01 Neuropharma, S.A. Uso de compuestos heterociclicos como agentes neurogenicos.
EP1749523A1 (fr) * 2005-07-29 2007-02-07 Neuropharma, S.A. Des inhibiteurs de GSK-3
NZ574619A (en) * 2006-07-18 2012-03-30 Univ Rochester THIADIAZOLIDINEDIONE DERIVATIVES including 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8)
WO2008012031A2 (fr) * 2006-07-25 2008-01-31 Universität Bern Bloqueurs de gsk3 de prévention et de traitement de pemphigus vulgaire
EP2061767B1 (fr) 2006-08-08 2014-12-17 Sanofi Imidazolidin-2,4-diones arylaminoaryl-alkyl-substituées, procédé de fabrication, médicaments les contenant et leur utilisation
JP5406030B2 (ja) 2006-10-21 2014-02-05 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
KR100829468B1 (ko) * 2007-01-17 2008-05-16 한국화학연구원 신규한 1,2,4-티아다이아졸리딘-3,5-다이온 화합물 및 이의제조방법
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2242745A1 (fr) * 2008-02-07 2010-10-27 Sanofi-Aventis Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2177510A1 (fr) 2008-10-17 2010-04-21 Universität des Saarlandes Modulateurs allostériques de protéine kinase
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011151359A1 (fr) * 2010-06-02 2011-12-08 Noscira, S.A. Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
WO2012065065A1 (fr) * 2010-11-12 2012-05-18 Follica, Inc. Procédés et compositions pour moduler la pousse de cheveux, la cicatrisation de plaie et la révision de cicatrice
WO2012078649A1 (fr) 2010-12-06 2012-06-14 Follica, Inc. Procédés destinés à traiter la calvitie et à favoriser la croissance des cheveux
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012120050A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
WO2012149335A2 (fr) * 2011-04-28 2012-11-01 Richard Neubig Inhibiteurs de petites molécules de protéines rgs
EP2527323A1 (fr) 2011-05-24 2012-11-28 Noscira, S.A. Dérivés de disulfure de carbonyle d'urée et leurs utilisations thérapeutiques
WO2012170657A1 (fr) * 2011-06-07 2012-12-13 Georgetown University Ciblage de gsk-3 bêta pour le traitement de la maladie de parkinson
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
PT2838888T (pt) * 2012-02-24 2017-07-18 Asd Therapeutics Partners Llc Tiadiazolidinedionas como inibidores da gsk-3
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
CN103992312A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
CN103992313A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途
WO2015075051A1 (fr) 2013-11-19 2015-05-28 Universitaet Des Saarlandes Inhibiteurs allostériques de protéines kinases c atypiques
WO2015155738A2 (fr) 2014-04-09 2015-10-15 Christopher Rudd Utilisation d'inhibiteurs ou d'activateurs de gsk -3 qui modulent l'expression de pd -1 ou de t-bet pour moduler l'immunité due aux lymphocytes t
CN106794175B (zh) 2014-06-12 2020-06-09 西达-赛奈医疗中心 用于治疗癌症的组合物
CN107151235B (zh) * 2016-03-04 2019-12-13 上海市计划生育科学研究所 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
CA3017341A1 (fr) * 2016-03-10 2017-09-14 Alma Mater Studiorum - Universita Di Bologna Traitement de troubles du cdkl5 au moyen de tideglusib inhibiteur de la gsk3 beta
WO2018226721A1 (fr) * 2017-06-06 2018-12-13 The J. David Gladstone Institutes Compositions et méthodes de réactivation d'un virus d'immunodéficience latent au moyen d'un inhibiteur de gsk-3
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113827592B (zh) * 2020-06-24 2024-06-18 中国科学院上海药物研究所 一种噻二唑烷二酮基化合物在治疗致病性感染中的应用
US20240173304A1 (en) 2021-02-24 2024-05-30 Teva Pharmaceuticals International Gmbh Solid state forms of tideglusib and process for preparation thereof
WO2022243973A1 (fr) 2021-05-21 2022-11-24 Amo Pharma Ltd. Procédé de traitement de maladies à médiation par des répétitions d'arn ayant un composé de liaison de répétition d'arn
EP4094760A1 (fr) 2021-05-24 2022-11-30 Consejo Superior De Investigaciones Científicas Thiadiazolidinones pour leur utilisation dans le traitement de la dystrophie scapulo-humérale
CN116675653A (zh) * 2022-07-22 2023-09-01 中国药科大学 氨基烷基取代的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
CN117986202B (zh) * 2024-04-03 2024-06-14 中国药科大学 具有ptpn2抑制活性的1，2，4-噻二唑烷-3，5-二酮化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1286964B1 (fr) * 2000-05-11 2007-07-04 Consejo Superior de Investigaciones Cientificas Inhibiteurs heterocycliques de la glycogene synthase kinase gsk-3
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
EP1586318A1 (fr) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiazolidinones comme inhibiteurs de GSK-3

Also Published As

Publication number Publication date
NO20064456L (no) 2006-10-02
KR101151647B1 (ko) 2012-06-08
TW200538119A (en) 2005-12-01
AU2005230392A1 (en) 2005-10-20
SI1586319T1 (sl) 2010-02-26
ATE446090T1 (de) 2009-11-15
CA2559740A1 (fr) 2005-10-20
HK1100426A1 (en) 2007-09-21
AR104417A2 (es) 2017-07-19
EP1586318A1 (fr) 2005-10-19
PL1586319T3 (pl) 2010-06-30
AR048820A1 (es) 2006-05-31
WO2005097117A1 (fr) 2005-10-20
RU2006139030A (ru) 2008-05-20
RU2379300C2 (ru) 2010-01-20
TWI352084B (en) 2011-11-11
DK1586319T3 (da) 2010-02-08
US20050222220A1 (en) 2005-10-06
ES2335505T3 (es) 2010-03-29
CN1946398A (zh) 2007-04-11
US7531561B2 (en) 2009-05-12
CA2559740C (fr) 2014-06-10
JP4995076B2 (ja) 2012-08-08
ZA200608221B (en) 2008-08-27
PT1586319E (pt) 2010-01-21
JP2007531782A (ja) 2007-11-08
KR20060131976A (ko) 2006-12-20
IL178125A0 (en) 2006-12-31
US20090233971A1 (en) 2009-09-17
MXPA06011194A (es) 2007-03-21
ECSP066858A (es) 2007-01-26
NO332751B1 (no) 2013-01-07
EP1586319A1 (fr) 2005-10-19
DE602005017215D1 (de) 2009-12-03
AU2005230392B2 (en) 2011-03-24
US8158661B2 (en) 2012-04-17
CN1946398B (zh) 2011-03-30
BRPI0508788A (pt) 2007-09-04
RS51340B (en) 2011-02-28
NZ549904A (en) 2010-08-27
EP1586319B1 (fr) 2009-10-21
HRP20100032T1 (hr) 2010-03-31
CY1109724T1 (el) 2014-08-13
IL178125A (en) 2012-01-31

Similar Documents

Publication Publication Date Title
MA28515B1 (fr) Inhibiteurs de gsk-3
EA200901373A1 (ru) Аминогетероциклические соединения
SG161217A1 (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
SV2006002055A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
SE0102299D0 (sv) Compounds
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
CL2007002288A1 (es) Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro
EA200801134A1 (ru) Замещенные бициклические пиримидоновые производные
ATE523495T1 (de) Substituierte pyrazolinverbindungen, deren herstellung und verwendung als medikamente
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EP1817312A4 (fr) Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
DOP2005000049A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegererativos
ATE403428T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
ATE435650T1 (de) 2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungen
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
UY28842A1 (es) Inhibidores de gsk-3